Every 65 seconds, another person receives a diagnosis for Alzheimer’s Disease, a disease that has no cure or ways to slow or halt its progression. Daunting statistics like this underscore the tremendous importance of finding a path forward to combat this deadly disease. While, the global pipeline has about 100 medicines in development for Alzheimer’s disease, solving the Alzheimer’s puzzle will require collaboration throughout the international community. Last month, the Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark demonstrated the spirit of partnership that can accelerate the path toward developing effective medicines and diagnostics for Alzheimer’s Disease.
After attending AAIC, President of Lilly Research Laboratories, Dr. Jan Lundberg, reflected on why he deeply values this collaboration as a researcher, but also as a son who lost his mother to this debilitating disease. Dr. Lundberg and millions of families worldwide know all too well the personal and financial cost of Alzheimer’s on patients and caregivers. With the number of diagnoses expected to increase to over 135 million people by 2050, the need for increased scientific innovation and collaboration becomes clear when looking at this disease’s global affect:
If the Copenhagen summit was any indicator, global collaboration between industry, academia, and advocacy organizations remains our best bet for how to move quickly to reduce the Alzheimer’s burden. By forging close partnerships, the global research community can build the stepping stones needed to discover how to diagnose and treat this mind-robbing disease.